


REMARKS

Claims 1, 3-6, 8-10, 16-18, 20-22, and 25-30 are pending in this application. Claims 3-4, 6, 8-10, 16-17, 20-22, 26-28, and 30 are cancelled herein as being drawn to a non-elected invention or to more clearly define the invention. Claims 31-32 are newly added. Accordingly, claims 5, 18, 25, 29, and 31-32 are presented for examination.

The Examiner has required restriction to one of two groups and has requested an election of species. In response to such restriction and species election Applicants wish to proceed as follows.

Applicants elect Group I drawn to a methods of treating cancer. Applicants elect for examination the species:



Several claims have been cancelled without prejudice herein and the remaining claims are amended thereby reflecting Applicants invention and species election.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "John L. Lemanowicz", with a stylized flourish at the end.

John L. Lemanowicz
Attorney for Applicants
Registration No. 37,380

Date: 29 March, 2007
Glaxo Smith Kline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
(919) 483-8247